Uncertain budget climate threatens safety of U.S. troops, veterans

WASHINGTON, D.C. – December 26, 2013 – Current budget restrictions and the threat of future cuts jeopardize the safety and mission readiness of U.S. troops, veterans’ health, and capabilities of the U.S. military’s tropical medicine research and development (R&D), said researchers today in an editorial published in PLOS Neglected Tropical Diseases.

Dengue Vaccine Initiative awarded grant from Germany for development of new dengue vaccines in Brazil and Vietnam

SEOUL, SOUTH KOREA - The Dengue Vaccine Initiative (DVI) announced today that it has received a 1 million Euro award from the German Federal Ministry of Education and Research (BMBF), the first time it has received such a grant from Germany. The funds will be used to support the development of new dengue vaccines in collaboration with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam.

New framework for neglected tropical diseases could unlock potential for world’s poorest people

WASHINGTON, D.C. – November 22 – A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities. The concept, “blue marble health,” emphasizes the role of the Group of 20 (G20) nations in tackling neglected tropical diseases (NTDs) to expedite poverty reduction efforts.

New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Pages